St. Jude Medical
This article was originally published in The Gray Sheet
Executive Summary
Firm receives IDE approval from FDA to begin its Post AV Node Ablation Evaluation (PAVE) clinical trial for patients with chronic atrial fibrillation receiving an 'ablate and pace' procedure, St. Jude announces Aug. 22. The 600-patient, 65-center study will compare the effects of left ventricular or biventricular pacing with right ventricular pacing, which is the current standard of care. The study, which will use St. Jude's Frontier stimulation device and Aescula left heart lead, will randomize patients to one of three arms. Patients in the left ventricular arm will also receive a right ventricular lead to provide backup right ventricular pacing. Endpoints include the six-minute walk test and quality of life assessment
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.